Lexaria Bioscience Forms New Scientific Advisory Board

Lexaria Bioscience Corp. has established a new Scientific Advisory Board (SAB) to enhance its drug delivery platform technology, led by President and CEO John Docherty. The SAB will include experts such as Dr. Michael Gibson, the newly appointed Chief Medical Advisor, who has a strong background in cardiovascular research and clinical trials. Docherty, who joined Lexaria in 2015, has extensive experience in pharmaceutical development and will leverage this to guide the company's strategic initiatives. The SAB will also focus on advancing Lexaria's patented DehydraTECH technology, particularly in applications for hypertension and GLP-1. Dr. Gibson's appointment is expected to significantly boost Lexaria's drug development capabilities and improve pharmacokinetic performance. Overall, this strategic move aims to strengthen Lexaria's position in the pharmaceutical sector and expedite the commercialization of its innovative drug delivery solutions.